In situ cancer vaccination using lipidoid nanoparticles
<jats:p>In situ vaccination is a promising strategy for cancer immunotherapy owing to its convenience and the ability to induce numerous tumor antigens. However, the advancement of in situ vaccination techniques has been hindered by low cross-presentation of tumor antigens and the immunosuppre...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association for the Advancement of Science (AAAS)
2021
|
| Online Access: | https://hdl.handle.net/1721.1/135648 |
| _version_ | 1826207316502904832 |
|---|---|
| author | Chen, Jinjin Qiu, Min Ye, Zhongfeng Nyalile, Thomas Li, Yamin Glass, Zachary Zhao, Xuewei Yang, Liu Chen, Jianzhu Xu, Qiaobing |
| author_facet | Chen, Jinjin Qiu, Min Ye, Zhongfeng Nyalile, Thomas Li, Yamin Glass, Zachary Zhao, Xuewei Yang, Liu Chen, Jianzhu Xu, Qiaobing |
| author_sort | Chen, Jinjin |
| collection | MIT |
| description | <jats:p>In situ vaccination is a promising strategy for cancer immunotherapy owing to its convenience and the ability to induce numerous tumor antigens. However, the advancement of in situ vaccination techniques has been hindered by low cross-presentation of tumor antigens and the immunosuppressive tumor microenvironment. To balance the safety and efficacy of in situ vaccination, we designed a lipidoid nanoparticle (LNP) to achieve simultaneously enhancing cross-presentation and STING activation. From combinatorial library screening, we identified 93-O17S-F, which promotes both the cross-presentation of tumor antigens and the intracellular delivery of cGAMP (STING agonist). Intratumor injection of 93-O17S-F/cGAMP in combination with pretreatment with doxorubicin exhibited excellent antitumor efficacy, with 35% of mice exhibiting total recovery from a primary B16F10 tumor and 71% of mice with a complete recovery from a subsequent challenge, indicating the induction of an immune memory against the tumor. This study provides a promising strategy for in situ cancer vaccination.</jats:p> |
| first_indexed | 2024-09-23T13:47:26Z |
| format | Article |
| id | mit-1721.1/135648 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T13:47:26Z |
| publishDate | 2021 |
| publisher | American Association for the Advancement of Science (AAAS) |
| record_format | dspace |
| spelling | mit-1721.1/1356482021-10-28T03:48:02Z In situ cancer vaccination using lipidoid nanoparticles Chen, Jinjin Qiu, Min Ye, Zhongfeng Nyalile, Thomas Li, Yamin Glass, Zachary Zhao, Xuewei Yang, Liu Chen, Jianzhu Xu, Qiaobing <jats:p>In situ vaccination is a promising strategy for cancer immunotherapy owing to its convenience and the ability to induce numerous tumor antigens. However, the advancement of in situ vaccination techniques has been hindered by low cross-presentation of tumor antigens and the immunosuppressive tumor microenvironment. To balance the safety and efficacy of in situ vaccination, we designed a lipidoid nanoparticle (LNP) to achieve simultaneously enhancing cross-presentation and STING activation. From combinatorial library screening, we identified 93-O17S-F, which promotes both the cross-presentation of tumor antigens and the intracellular delivery of cGAMP (STING agonist). Intratumor injection of 93-O17S-F/cGAMP in combination with pretreatment with doxorubicin exhibited excellent antitumor efficacy, with 35% of mice exhibiting total recovery from a primary B16F10 tumor and 71% of mice with a complete recovery from a subsequent challenge, indicating the induction of an immune memory against the tumor. This study provides a promising strategy for in situ cancer vaccination.</jats:p> 2021-10-27T20:24:26Z 2021-10-27T20:24:26Z 2021 2021-07-15T16:02:37Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/135648 en 10.1126/sciadv.abf1244 Science Advances Creative Commons Attribution NonCommercial License 4.0 https://creativecommons.org/licenses/by-nc/4.0/ application/pdf American Association for the Advancement of Science (AAAS) Science Advances |
| spellingShingle | Chen, Jinjin Qiu, Min Ye, Zhongfeng Nyalile, Thomas Li, Yamin Glass, Zachary Zhao, Xuewei Yang, Liu Chen, Jianzhu Xu, Qiaobing In situ cancer vaccination using lipidoid nanoparticles |
| title | In situ cancer vaccination using lipidoid nanoparticles |
| title_full | In situ cancer vaccination using lipidoid nanoparticles |
| title_fullStr | In situ cancer vaccination using lipidoid nanoparticles |
| title_full_unstemmed | In situ cancer vaccination using lipidoid nanoparticles |
| title_short | In situ cancer vaccination using lipidoid nanoparticles |
| title_sort | in situ cancer vaccination using lipidoid nanoparticles |
| url | https://hdl.handle.net/1721.1/135648 |
| work_keys_str_mv | AT chenjinjin insitucancervaccinationusinglipidoidnanoparticles AT qiumin insitucancervaccinationusinglipidoidnanoparticles AT yezhongfeng insitucancervaccinationusinglipidoidnanoparticles AT nyalilethomas insitucancervaccinationusinglipidoidnanoparticles AT liyamin insitucancervaccinationusinglipidoidnanoparticles AT glasszachary insitucancervaccinationusinglipidoidnanoparticles AT zhaoxuewei insitucancervaccinationusinglipidoidnanoparticles AT yangliu insitucancervaccinationusinglipidoidnanoparticles AT chenjianzhu insitucancervaccinationusinglipidoidnanoparticles AT xuqiaobing insitucancervaccinationusinglipidoidnanoparticles |